Physician profile
Matthew D Mcclain
NPI 1962517276
$5,260.89
in general payments reported to CMS, 2019-2025
41 companies · $906 in 2025
The $906 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $138 · 2021: $233 · 2022: $1,004 · 2023: $1,256 · 2024: $1,135 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,365.75 | 2021-2025 | |
| Pfizer INC. | $510.02 | 2019-2025 | |
| Lilly USA, LLC | $353.40 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $343.62 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $248.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $240.28 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.08 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.54 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $180.13 | 2019-2022 | |
| Amarin Pharma, INC. | $167.53 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $106.45 | 2019-2024 | |
| Amgen INC. | $105.83 | 2024-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $91.83 | 2024-2025 | |
| Allergan, INC. | $77.96 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.